Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma

Figure 6 Gene signature set predicts hepatic artery infusion chemotherapy response[76]. A: Mutational landscape of the total 96 patients' sequence data by the next-generation sequencing analysis (Each row represents a gene, each column represents a sample, and different colors represent types of mutations); B: Heatmap of the correlation of 15-gene model and tumor response to the hepatic artery infusion chemotherapy (HAIC) treatment in the total 96 patients underwent genomic sequencing (Row: One sample of the mutation of the chosen 15 polymorphic sites, Column: One polymorphic site of the 90 samples). The right two columns show the tumor response to the HAIC treatment (green: response; blue: non-response); C: Survival outcomes between the HAIC responders and the HAIC nonresponders identified by the 15- mutant-gene prediction model; C-E: Kaplan-Meier estimates of (C) overall survival, (D) progression-free survival, and (E) intrahepatic tumor progression-free survival (ITPFS). Citation: Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol 2022; 40: 468-480. Copyright © 2022. Published by American Society of Clinical Oncology. The authors have obtained the permission for figure using (Supplementary material).